Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Duster340on Sep 12, 2022 2:49pm
116 Views
Post# 34957391

This is where the real money is

This is where the real money isto bad these guys no zip about cancer)

In nod to JFK, Biden returns to Boston to relaunch cancer moonshot initiative

President Biden spoke during a "Cancer Moonshot," event in the East Room of the White House, Feb. 2, 2022, in Washington.
President Biden spoke during a "Cancer Moonshot," event in the East Room of the White House, Feb. 2, 2022, in Washington.ALEX BRANDON/ASSOCIATED PRESS

President Biden will visit Boston Monday to deliver a speech on his Cancer Moonshot Initiative, which aims to cut the cancer death rate in half over the next 25 years and provide greater support to caregivers and survivors.

The president will give the speech at the John F. Kennedy Presidential Library 60 years to the day of President John F. Kennedy’s 1962 moonshot address at Rice University in Houston.

Biden launched the cancer moonshot at the tail end of the Obama administration. After a hiatus during the Trump administration, the president relaunched the initiative in February.

 
 

<< Previous
Bullboard Posts
Next >>